✦ LIBER ✦

Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA Trial

✍ Scribed by Cortes, J. E.; Kim, D.-W.; Kantarjian, H. M.; Brummendorf, T. H.; Dyagil, I.; Griskevicius, L.; Malhotra, H.; Powell, C.; Gogat, K.; Countouriotis, A. M.; Gambacorti-Passerini, C.

Book ID: 125534146
Publisher: American Society of Clinical Oncology
Year: 2012
Tongue: English
Weight: 161 KB
Volume: 30
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2011.38.7522

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Safety of bosutinib versus imatinib in t

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia

✍ Gambacorti-Passerini, Carlo; Cortes, Jorge E.; Lipton, Jeff H.; Dmoszynska, Anna 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB

Dasatinib versus Imatinib in Newly Diagn

Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

✍ Kantarjian, Hagop; Shah, Neil P.; Hochhaus, Andreas; Cortes, Jorge; Shah, Sandip 📂 Article 📅 2010 🏛 Massachusetts Medical Society 🌐 English ⚖ 260 KB

Imatinib in patients with newly diagnose

Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Stephen G. O'Brien; Michael W.N. Deininger 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 99 KB

Imatinib for newly diagnosed chronic-pha

Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: results of a prospective study in Japan

✍ Tadashi Nagai; Jin Takeuchi; Nobuaki Dobashi; Yuzuru Kanakura; Shuichi Taniguchi 📂 Article 📅 2010 🏛 Carden Jennings Publishing 🌐 English ⚖ 284 KB

Dasatinib: From Treatment of Imatinib-Re

Dasatinib: From Treatment of Imatinib-Resistant or -Intolerant Patients With Chronic Myeloid Leukemia to Treatment of Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia

✍ Brian L. Abbott 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 319 KB

Cost-effectiveness of imatinib versus in

Cost-effectiveness of imatinib versus interferon-α plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia

✍ Shelby D. Reed; Kevin J. Anstrom; Jennifer A. Ludmer; G. Alastair Glendenning; K 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 119 KB 👁 1 views

## Abstract ## BACKGROUND Despite a lack of long‐term data, imatinib has become standard therapy for patients with newly diagnosed chronic‐phase chronic myeloid leukemia (CML) who are not candidates for allogeneic stem cell transplantation. In the current study, the authors estimated the increment